Journal
CELL DEATH & DISEASE
Volume 12, Issue 1, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41419-020-03311-1
Keywords
-
Categories
Funding
- National Natural Science Foundation of China
- Samuel Waxman Cancer Research Foundation
- National Key Research and Development Program [2016YFC0902800]
- Key Project of Natural Science Foundation of China [81530006]
- Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research [2019CXJQ01]
- Natural Science Foundation of China [81870112, 81770171, 81970134]
- Shanghai Science and Technology Development Funds [18ZR1423600]
- Innovative Research Team of High-level Local Universities in Shanghai
Ask authors/readers for more resources
The study reveals that palmitoylation of GNA13 plays a crucial role in regulating its tumor suppressor function and negatively regulating BCL2 expression in GCB-DLBCL cells. BCL2 inhibitors have been found to effectively kill GNA13-deficient GCB-DLBCL cells in a cell-based chemical screen. Targeting GNA13's palmitoylation enhances the sensitivity of GCB-DLBCL to BCL2 inhibitors, suggesting a potential combination therapy approach for treating GCB-DLBCL with wild-type GNA13.
GNA13, encoding one of the G protein alpha subunits of heterotrimeric G proteins that transduce signals of G protein-coupled receptors (GPCR), is frequently mutated in germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) with poor prognostic outcomes. Due to the undruggable nature of GNA13, targeted therapy for these patients is not available. In this study, we found that palmitoylation of GNA13 not only regulates its plasma membrane localization, but also regulates GNA13's stability. It is essential for the tumor suppressor function of GNA13 in GCB-DLBCL cells. Interestingly, GNA13 negatively regulates BCL2 expression in GCB-DLBCL cells in a palmitoylation-dependent manner. Consistently, BCL2 inhibitors were found to be effective in killing GNA13-deficient GCB-DLBCL cells in a cell-based chemical screen. Furthermore, we demonstrate that inactivating GNA13 by targeting its palmitoylation enhanced the sensitivity of GCB-DLBCL to the BCL2 inhibitor. These studies indicate that the loss-of-function mutation of GNA13 is a biomarker for BCL2 inhibitor therapy of GCB-DLBCL and that GNA13 palmitoylation is a potential target for combination therapy with BCL2 inhibitors to treat GCB-DLBCL with wild-type GNA13.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available